Currently we test and support the following browsers:
Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
Scientists at St. Jude Children’s Research Hospital have more evidence that age matters when it comes to the devastating brain tumors called high-grade gliomas (HGGs).
St. Jude Children’s Research Hospital-Washington University Pediatric Cancer Genome Project offers new leads to improved outcomes for children with high-grade glioma brain tumors; particularly youngest patients. (Suzanne Baker, PhD, and Jinghui Zhang, PhD)
Pediatric Cancer Genome Project scientists begin to uncover treasures.
St. Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project provides first evidence linking cancer to mutations in genes involved in DNA organization. (Dr. Suzanne Baker)
For many years, St. Jude researchers have been investigating the connection between genetics and pediatric cancer. Those approaches continue to have dramatic implications for clinical care.
Study led by St. Jude Children’s Research Hospital scientists points to possible new treatment targets for diffuse intrinsic pontine gliomas; may tip the scales in the current debate about tumor biopsies.
St. Jude Children’s Research Hospital investigators use a novel model system to show how specific mutations can induce glioma formation in multiple regions of the brain and to begin studying patient response to a new generation of targeted therapies.
Clinicians and researchers chart a course to find cures for high-grade gliomas.
The most comprehensive analysis yet of the genetic imbalances at the heart of childhood brain tumors known as high-grade gliomas (HGGs) identified a cancer gene that is unusually active in some tumors and is now the focus of a St. Jude Children’s Research Hospital clinical trial.
Investigators at St. Jude Children's Research Hospital used an experimental anti-cancer drug to prevent or reverse abnormal brain cell growth that is caused by lack of the anti-cancer gene Pten.